Signia Therapeutics

Signia Therapeutics is an innovative French start-up co-founded in April 2017 by a team of four French & Canadian scientists.

SIGNIA Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.

Signia Therapeutic’s drug discovery platform has already demonstrated its significant potential with proofs-of-concept already established for several market-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications. Signia Therapeutics's most advanced product is under a Phase II multicentric clinical evaluation (FLUNEXT trial) for the evaluation of one very promising antiviral candidate, with final results expected in 2019-2020.

Signia Therapeutics was laureate of the i-Lab 2017 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance. The company has also been awarded the Seal of Excellence by the EU H2020 Framework Programme for Research and Innovation in 2018.